Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Tofersen in Amyotrophic Lateral Sclerosis: NCT07294144 Clinical Landscape Report 2026
16 September 2026
NCT07294144 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Forazapadin in Tabes Dorsalis: NCT07287189 Clinical Landscape Report 2026
16 September 2026
NCT07287189 clinical landscape for Tabes Dorsalis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Telitacicept in Myasthenia Gravis, Ocular: NCT07298928 Clinical Landscape Report 2026
16 September 2026
NCT07298928 clinical landscape for Myasthenia Gravis, Ocular: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: NCT07304154 Clinical Landscape Report 2026
16 September 2026
NCT07304154 clinical landscape for Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: endpoints, sponsor, phase, geography, readouts, asset context…
9 min read
Polyenephosphatidyl Choline in Diabetes Mellitus, Type 2: NCT07303803 Clinical Landscape Report 2026
16 September 2026
NCT07303803 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HP-515 in Metabolic Dysfunction Associated Steatohepatitis: NCT07308548 Clinical Landscape Report 2026
16 September 2026
NCT07308548 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Tegacorat in Muscular Dystrophy, Duchenne: NCT07317063 Clinical Landscape Report 2026
16 September 2026
NCT07317063 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pridopidine in Amyotrophic Lateral Sclerosis: NCT07322003 Clinical Landscape Report 2026
16 September 2026
NCT07322003 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Galunisertib in Amyotrophic Lateral Sclerosis: NCT07321860 Clinical Landscape Report 2026
16 September 2026
NCT07321860 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ECC-4703 in Metabolic Dysfunction Associated Steatohepatitis: NCT07334080 Clinical Landscape Report 2026
16 September 2026
NCT07334080 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
FAP-Targeted CAR-DC(The Second Affiliated Hospital Zhejiang University) in Idiopathic Pulmonary Fibrosis: NCT07329959 Clinical Landscape Report 2026
16 September 2026
NCT07329959 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tazbentetol in Amyotrophic Lateral Sclerosis: NCT07325591 Clinical Landscape Report 2026
16 September 2026
NCT07325591 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.